Pre or post-operative medical treatment with nafarelin in stage III-IV endometriosis: a French multicenter study

What Was Tested

The paper reports a study of Nafarelin in the context of endometriosis, published as a randomized controlled trial.

Who Took Part

The age groups tagged for this paper are adults, women only.

Fifty-five patients with stage III and IV endometriosis.

The severity of endometriosis was assessed at the time of laparoscopy and patients were randomized to have either laparosopic surgery at that time following 6 months of nafarelin therapy (n=28), or laparoscopic surgery following 6 months of nafarelin therapy (n=25).

How the Study Was Run

In design terms this was a randomized, double-blind and multicenter study.

Because people in this Nafarelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Nafarelin study, the assignments were hidden from both participants and investigators until the end.

More than one site took part, so the participants came from several places.

The methods mention a period of 6 months.

Eight university hospitals and two private practice institutions in France.

All had 200 microg intranasal nafarelin twice a day for 6 months and a second look laparoscopy.

What Was Measured

PubMed files the paper under topics including Endometriosis, Hormones, Laparoscopy and Nafarelin.

What This Means in Plain Language

The paper is a randomized, double-blind and multicenter study of Nafarelin in people with endometriosis over 6 months.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1998 (European journal of obstetrics, gynecology, and reproductive biology), a journal based in Ireland.

More context: the Nafarelin compound page, Endometriosis research.